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Background: Prostate cancer is a global health concern. In Iran, its epidemiology is not precisely 
recognized. We aimed to evaluate incidence of prostate cancer among Iranian populations.
Methods: In this systematic review, we searched the databases PubMed, Web of Sciences, 
Scopus and Google Scholar for English studies and the databases Magiran, Scientific Information 
Database, IranMedex and IranDoc for Persian studies, using related keywords. The cross-
sectional articles published from inception to 31 December 2018 were included. Meta-analysis 
was conducted on the collected data with STATA software using random effects model.
Results: Out of 763 articles initially obtained, 9 articles were finally included after applying 
the predefined exclusion criteria. Analysis of 9 studies on the incidence of prostate cancer 
showed a crude rate of 7.1 per 100 000 population (95% confidence interval [CI]: 5.6-8.6). Also, 
the pooled age-standardized incidence rate was 8.7 per 100 000 (95% CI: 6.7-10.4). Studies 
performed in the period 2004-2012 had significantly a higher pooled estimate of the crude 
incidence rate (9.2 per 100 000 [95% CI: 7.9-10.4]) compared with those conducted in the 
period 1996-2003 (4.5 per 100 000 [95% CI: 2.8-6.2]). This trend was also observed based on 
the age-standardized incidence rate (11 per 100 000 [95% CI: 9.4-12.5] versus 6.3 per 100 000 
[95% CI: 4-8.5]).
Conclusion: Despite low rate of prostate cancer occurrence in Iran, it is recommended 
that preventive measures be taken against this disease by health policy makers. Also, more 
epidemiological studies are needed to better find out the pattern of prostate cancer among 
Iranian populations.
Article History:
Received: 29 Oct. 2018
Accepted: 27 Mar. 2019









Phone: +98 11 32199936,
Address: Department of 
Urology, Babol University of 
Medical Sciences, Ganjafrooz 






Citation: Moradi A, Zamani M, Moudi E. A systematic review and meta-analysis on incidence of prostate cancer in Iran. Health Promot 
Perspect. 2019;9(2):92-98. doi: 10.15171/hpp.2019.13.
Systematic Review
Background
Prostate cancer is presently one of the major health 
concerns in the world.1 It is globally the second most 
frequent malignancy and the fifth leading cause of cancer 
deaths for males.2,3 Its epidemiology varies between 
different regions, that is, western countries has lower rates 
than eastern countries.4
According to the Global Burden of Disease study, 1.4 
million new cases of prostate cancer was recorded in 2016 
and it was determined as the most common incident 
cancer in males. Also, 381 000 deaths were attributed 
to this disease.5 It is expected that new cases of prostate 
cancer and the death number will reach to 1.7 million and 
499 000 people around the world by 2030, respectively.6
Iran, a developing country, is experiencing an 
epidemiological transition. The burden of cancer has been 
associated with an ascending trend in this country over 
the past decades.7,8 According to the report by Ministry 
of Health in Iran, cancer is the third cause of death and 
prostate cancer is one of the ten most frequent cancers.9 A 
previous study in 2005 revealed that it is the second most 
prevalent cancer among genitourinary cancers in Iranian 
males.10 So, strategic planning is needed to better control 
this disease in Iran. To accomplish this aim, determining 
epidemiological patterns of the cancer is necessary. Cancer 
registries established across Iran have been a positive step 
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in this regard. However, no inclusive and precise report is 
available on the epidemiology of prostate cancer in this 
country. For this reason, we systematically reviewed the 
literature on the incidence of prostate cancer in Iran and 
attempted to provide comprehensive information about 
this subject. These data would be helpful to health policy-
makers and physicians for better planning and prevention 
and also making decisions on management and treatment 
of the patients with prostate cancer. 
Materials and Methods
Information sources and search strategy
The authors undertook a literature search of the following 
databases from inception to 31 December 2018: PubMed, 
Web of Sciences, Scopus and Google Scholar. The related 
terms were searched in the Medical Subject Headings 
(MeSH) database, and finally, the keywords “prostatic 
neoplasm” OR “prostatic neoplasms” OR “prostate cancer” 
OR “prostate cancers” OR “cancer of prostate” OR “cancer 
of the prostate” AND “epidemiology” OR “prevalence” 
OR “incidence” OR “frequency” AND “Iran” OR “Iranian” 
were selected. The search was limited to Title/Abstract. 
It was also limited to the affiliation “Iran”. The Persian 
equivalents of the keywords were used for searching 
the national Persian databases, including Magiran and 
Scientific Information Database (SID), IranMedex and 
IranDoc. We also manually searched the reference lists of 
each included article for additional sources.
The present systematic review and meta-analysis 
was conducted according to the PRISMA (Preferred 
reporting items for systematic review and meta-analysis) 
guideline.11 The protocol of this systematic review and 
meta-analysis has been registered in the PROSPERO 
registry (CRD42018102421).
Inclusion and exclusion criteria
We included all English and Persian cross-sectional studies 
that reported the incidence of prostate cancer among 
Iranian population. The exclusion criteria for our study 
were the following: Reviews, case reports, correspondences 
and editorials, Duplicate articles or studies reporting 
on the same population, Case-control studies, Studies 
included subjects with other specific conditions (e.g., 
cancer of other organs, renal transplantation), and Articles 
without explicit methodology or results.
Study selection and data extraction
Two authors (MZ and EM) independently assessed the 
study eligibility by reviewing the titles and abstracts of 
all potential citations. Discrepancies were resolved by 
consensus between the reviewers. Full-text of the relevant 
articles was assessed. The following data were extracted 
from each included study: first author’s name, location of 
study, study period, population size, diagnostic method, 
and crude rate and/or age-standardized rate (ASR) of the 
incidence. If multiple publications of the same population 
were retrieved, the one giving more detail was chosen.
Statistical analysis
The meta-analysis was conducted using the statistical 
software STATA V13 (StataCorp, College Station, 
TX, USA). Point estimates and their 95% confidence 
intervals (CIs) were calculated. When a study reported 
the incidence rate in different times, we included them 
as a separate report in the analysis, if applicable. We 
performed a subgroup analysis according to the region 
for incidence of prostate cancer. Also, a sub-analysis was 
conducted to evaluate the incidence stratified by time. In 
this regard, we split the study period into 1996-2004 and 
2005-2012. Heterogeneity was checked using the I2 index. 
We used random effects model to combine the effect 
estimates from studies. The cumulative meta-analysis was 
conducted based on year of publication. Publication bias 
was assessed using a funnel plot, Begg’s and Egger’s tests.
Results
 The search yielded a total 763 articles: 562 from the English 
databases and 201 from the Persian databases. After 
assessing title and abstract, 403 studies were excluded due 
to meeting the predefined exclusion criteria. Then, full-
text of the remaining 19 articles was retrieved for more 
detailed evaluation. The manual search found 1 additional 
article. Finally, 9 papers were included in the study. Figure 
1 shows the results of search strategy according to the 
PRISMA (Preferred reporting items for systematic review 
and meta-analysis) flow diagram.11
Incidence of Prostate Cancer
A total of 9 articles on the incidence were finally included 
(Table 1). Three studies reported the incidence rate of 
prostate cancer in national populations and others were 
restricted to the local cancer registries, including Ardabil, 
Fars, Golestan, Guilan, Kerman, Mazandaran, Semnan 
and Tehran. The studies period ranged from 1996 to 2012. 
All of the methods used for diagnosis of prostate cancer 
was histopathology. The overall pooled crude incidence 
rate of the cancer was 7.1 per 100 000 population (95% 
CI: 5.6-8.6) (Figure 2a). Heterogeneity existed between 
estimates (I2=99.6%; P < 0.001). In addition, the ASR 
was estimated to be 8.7 per 100 000 (95% CI: 6.7-10.4; 
I2=99.6%; P < 0.001) (Figure 2b).
 An analysis was also conducted on the nation-wide 
reports to estimate the incidence rate among national 
population. As exhibited in Figure 3a, the pooled crude 
incidence rate was 8.2 per 100 000 (95% CI: 6.6-9.8; 
I2=99.6%; P < 0.001). Besides, the pooled ASR incidence 
was 10 per 100 000 (95% CI: 8-12.1; I2=99.6%; P < 0.001) 
(Figure 3b).
The results of subgroup analysis indicated that the crude 
incidence rate of prostate cancer is significantly higher in 
the period 2004-2012 (9.2 per 100 000 population [95% 
CI: 7.9-10.4; I2=99.2%; P < 0.001]) in comparison with 
1996-2003 (4.5 per 100 000 population [95% CI: 2.8-6.2; 
I2=99.1%; P < 0.001]) (Figure 4a). This increasing trend 
was also found for the ASR incidence (11 per 100 000 
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Figure 1. Flow diagram of study selection.







Crude rate (per 
100 000)
ASR (per 100 000) Author
Ardabil 1996-2000 2636364 Histopathology ICD-O-3 2.2 3.4 Sadjadi12 (A)
Fars 1998-2002 10666667 Histopathology ICD-O 2.1 3.5 Masoompour13
Fars 2007-2010 8397247 Histopathology ICD-O 10.17 12.99 Masoompour14
Golestan 1996-2000 3312500 Histopathology ICD-O-3 3.2 5.2 Sadjadi12 (D)
Guilan 1996-2000 5055556 Histopathology ICD-O-3 3.6 4.4 Sadjadi12 (B)
Kerman 1996-2000 5000000 Histopathology ICD-O-3 2.4 3.2 Sadjadi12 (E)
Kerman 2010 90692 Histopathology NA 41.9 NA Mohamadkhani15
Mazandaran 1996-2000 4309091 Histopathology ICD-O-3 5.5 6.1 Sadjadi12 (C)
Nation-wide 2003 34096916 Histopathology ICD-O C61 4.54 5.4 Pakzad16 (A)
Nation-wide 2004 34706868 Histopathology ICD-O C61 5.97 7.24 Pakzad16 (B)
Nation-wide 2005 36148738 Histopathology ICD-O C61 7.53 9.22 Pakzad16 (C)
Nation-wide 2006 36023018 Histopathology ICD-O C61 7.82 9.57 Pakzad16 (D)
Nation-wide 2007 36166098 Histopathology ICD-O C61 8.79 10.91 Pakzad16 (E)
Nation-wide 2008 35998071 Histopathology ICD-O C61 10.37 12.8 Pakzad16 (F)
Nation-wide 2009 39346939 Histopathology ICD-O 9.8 12.59 Basiri17
Nation-wide 2012 38420561 Histopathology - 10.7 12.6 Almasi9
Semnan 1998-2002 37415 Histopathology ICD-10 147 150 Babaei18
Tehran 1998-2001 15242718 Histopathology ICD-O-2 & ICD-O-3 10.3 15.6 Mohagheghi19
NA, Not applicable; ASR, Age-standardized rate.
 























n Additional records identified 
through other sources 
(n = 1) 
Records after duplicates removed 
(n =422) 
Records screened for title 
and abstract 
(n = 422) 
Records excluded 
(n =403) 
Full-text articles assessed 
for eligibility 
(n = 19) 
Full-text articles excluded, 
with reasons (n =12) 
• The same data (n=7) 
• Subjects with specific 
disease (n=1) 
• Lack of clear 
methodology or results 
(n=4) Studies included  
(n = 9) 
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[95% CI: 9.4-12.5; I2=99.2%; P < 0.001] in the period 2004-
2012 versus 6.3 per 100 000 in the period 1996-2003 [95% 
CI: 4-8.5; I2=99.1%; P < 0.001]) (Figure 4b).
A cumulative meta-analysis of the included studies was 
performed based on publication year. Figure 5 exhibits the 
cumulative meta-analysis.
Visual inspection of the funnel plot did not indicate any 
potential publication bias (Figure 6a). Begg’s and Egger’s 
tests also showed no significant evidence of publication 
bias among the included studies (Begg’s test, P = 0.161; 
Egger’s test, P = 0.204). Figures 6b and 6c are related to 
Begg’s and Egger’s tests, respectively.
Discussion
This review presented pooled epidemiological data of 
prostate cancer in Iran. The overall ASR incidence of 
the prostate cancer was estimated to be 8.7 per 100 000 
population, and this rate was 10 per 100 000 population 
based on nation-wide reports. Our figure is near to the 
report by GLOBOCAN in 2018, with an estimated rate 
of 16.6 per 100 000.20 Distribution of prostate cancer 
regionally changes worldwide. In 2018, its incidence was 
highest in Northern America, Europe and Oceania with 
ASR of 130, 125.1 and 113.8 per 100 000, respectively, and 
the lowest in Asia and Africa with ASR of 12.8 and 12.6 
per 100 000, respectively.20 These variations can also be 
observed at lower scales between the neighboring countries 
with a close proximity. In comparison to Iran, prostate 
cancer was reported to have a ASR of 4.5 per 100 000 in 
Afghanistan versus 41.7 per 100 000 in Turkey.20 Recently, 
a meta-analysis was published on incidence of prostate 
cancer in Iran and reported an ASR of 9.11 per 100 000,21 
however, our article has superiorities over that. Firstly, 
we presented both of pooled crude and ASR incidence of 
prostate cancer in our study. Secondly, we tried to exclude 
the duplicates to prevent overestimation of the values. 
Thirdly, we did a sub-group analysis by study period to 
assess the trend of prostate cancer incidence.
Altogether, it is known that occurrence of prostate 
cancer is considerably more in developed countries than 
in developing countries. This difference can be mainly due 
to population-based prostate cancer screening and use of 
advanced diagnostic methods (PSA testing and TURP) 
which are expanding in most developed countries, whereas 
they have not been widely taken into consideration in 
developing communities.22-24 Hence, it is predictable that 
number of new cases will increase by earlier detection of 
the cancer in western nations more than in the eastern 
nations. 
As determined, incidence of prostate cancer in Iran 
had a higher rate in the period 2004-2012 in comparison 
(a)
(b)
Figure 2. (a) Forest plot of the pooled crude incidence of prostate 
cancer in Iran. (b) Forest plot of the pooled age-standardized 
incidence of prostate cancer in Iran.
Figure 3. (a) Forest plot of the pooled crude incidence of prostate 
cancer among national population in Iran. (b) Forest plot of the 
pooled age-standardized incidence of prostate cancer among 
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(a)
(b)
Figure 4. (a) Forest plot of the pooled crude incidence of prostate 
cancer by study period. (b) Forest plot of the pooled age-standardized 
incidence of prostate cancer by study period.
Figure 5. Result of cumulative meta-analysis based on year of 
publication.
Figure 6. (a) Funnel plot to assess publication bias across the 
studies. (b) The Begg’s test for publication bias. (c) The Egger’s test 
for publication bias.
with 1996-2003, which is in consistent with the global 
increasing trend.4,25 This increase in the incidence can 
not only result from success of screening program for 




and behavioral factors, such as smoking and westernized 
diets.7,26,27
Genetic factors have been discussed to be linked to the 
prostate cancer in some articles on Iranian population. 
For instance, genotypes of rs4977574, rs1333048 and 
rs10757278 from INK4 locus, and rs12826786 T allele 
from HOX transcript antisense RNA, were recently 
reported.28,29 A case-control study in west of Iran also 
showed that western unhealthy dietary pattern was 
associated with increased risk of prostate cancer (OR: 
3.4), while a healthy dietary pattern was associated with 
decreased risk of prostate cancer (OR: 0.24).30
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A limitation for our study was the significant 
heterogeneity seen for the pooled analyses. In relation to 
the incidence, we witnessed high heterogeneity even after 
analysis of the data on national populations (excluding 
the reports at local scales). Altogether, a number of factors 
could be considered as sources of heterogeneity, such 
as variations in population size and age distributions, 
study date, and diagnostic criteria discussed before. High 
heterogeneity is usually seen in systematic reviews and 
meta-analyses on epidemiological surveys and it is not 
unexpected.31 Lack of clear information in four studies 
cause excluding them, while their data might be useful to 
the analyses. A good point about our review was lack of 
publication bias among individual studies, suggesting that 
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